

**Table SIII. Baseline and follow-up data on obese patients with moderate to severe plaque psoriasis who underwent bariatric surgery and matched patients without history of bariatric surgery**

	Surgery group with plaque psoriasis						Control group with plaque psoriasis					
	Baseline	<i>n</i>	Follow-up >0 but ≤ 1 years	<i>n</i>	Follow-up ≥ 1 but ≤ 2 years	<i>n</i>	Baseline	<i>n</i>	Follow-up >0 but ≤ 1 years	<i>n</i>	Follow-up ≥ 1 but ≤ 2 years	<i>n</i>
Body mass index, kg/m <sup>2</sup> , median (IQR)	38.9 (35.8–42.1)	34	31.4 (26.9–33.3)	26	29.0 (26.0–32.9)	22	32.5 (31.2–35.6)	60	32.6 (30.9–35.1)	55	33.6 (30.9–37.3)	32
Weight, kg, median (IQR)	118.3 (105.0–134.5)	36	89.4 (82.0–103.0)	26	86.5 (77.0–105.3)	22	100.0 (94.5–109.0)	60	102.0 (94.0–108.0)	55	98.8 (86.6–109.5)	32
PASI, median (IQR)	4.5 (2.1–8.3)	36	4.9 (2.5–7.8)	25	1.8 (0.6–4.4)	22	5.1 (2.3–9.4)	60	3.0 (1.8–7.1)	52	3.0 (1.2–5.6)	31
DLQI, median (IQR)	1.0 (0.0–4.5)	36	2.0 (0.0–4.0)	23	2.0 (1.0–3.0)	21	3.5 (1.0–11.0)	58	2.0 (0.0–9.0)	55	2.0 (0.0–5.0)	31
Pso treatment, <i>n</i> (%)		36		36		36		60		60		60
No treatment	2 (5.6)		11 (30.6)		16 (44.4)		8 (13.3)		9 (15.0)		30 (50.0)	
Non-biologic systemic	19 (52.8)		17 (47.2)		12 (33.3)		34 (56.7)		31 (51.7)		11 (18.3)	
Biologic systemic	15 (41.7)		8 (22.2)		8 (22.2)		18 (30.0)		20 (33.3)		19 (31.7)	
PsoA, <i>n</i> (%)		36		26		22		60		55		32
Ongoing	12 (33.3)		9 (34.6)		4 (18.2)		15 (25.0)		14 (25.5)		11 (34.4)	
Previous	5 (13.9)		4 (15.4)		4 (18.2)		3 (5.0)		2 (3.6)		1 (3.1)	
No	15 (41.7)		10 (38.5)		12 (54.5)		29 (48.3)		29 (52.7)		14 (43.8)	
Unknown	4 (11.1)		3 (11.5)		2 (9.1)		13 (21.7)		10 (18.2)		6 (18.8)	

*n* denotes 100% of participants in each category.

IQR: interquartile ranges; DLQI: Dermatology Life Quality Index; PASI: Psoriasis Area Severity Index; Pso: psoriasis; PsoA: psoriatic arthritis.